author-photo

John M. Lambert

ImmunoGen, Inc.

111

Papers

5145

Citations

Citation Trend

Filter By

Papers (71) Sort By

Journal Conference Others

The Secret Lives of Paleoindians: Regional Exchange and Social Networks in the Western Great Lakes

2019
- Thomas J. Loebel
- John M. Lambert
Show All
- Source
- Cite
- Save
Citations (0)
CHAPTER 2. Design Factors Important for Antibody–Drug Conjugate (ADC) Payloads

2019
- John M. Lambert
Show All
- Source
- Cite
- Save
Citations (1)
A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates Benefits of Lysine Conjugation

2019 Molecular Pharmaceutics
Show All
- Source
- Cite
- Save
Citations (14)
Synthesis and Assessment of the Folsom Record in Illinois and Wisconsin (Annual Meeting of the SAA)

2017
Show All
- Source
- Cite
- Save
Citations (0)
Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates

2017 Bioconjugate Chemistry
Show All
- Source
- Cite
- Save
Citations (84)
1. Typical Antibody–Drug Conjugates

2016
- John M. Lambert
Show All
- Source
- Cite
- Save
Citations (7)
A new, triglycyl peptide linker for antibody-drug conjugates (ADCs) with improved targeted killing of cancer cells

2016 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (19)
New developments for antibody-drug conjugate-based therapeutic approaches.

2016 Current Opinion in Immunology
- Bart De Goeij
- John M. Lambert
Show All
- Source
- Cite
- Save
Citations (174)
Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay.

2015 Pharmaceutical Research
Show All
- Source
- Cite
- Save
Citations (10)
IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (89)